## JC06 Rec'd PCT/PTO 23 MAR 2005

PTO-1390(Rev. 12-2004)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

ATTORNEY 'S DOCKET NO .: PRD-0032-USPCT1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) 371 CONCERNING A FILING UNDER 35 U.S.C.

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

CONCERNING A FILING UNDER	10/528928							
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED						
PCT/EP2003/010092	09.09.2003	27.09.2002						
TITLE OF INVENTION N-11 TRUNCATED AMYLOID-BETA MONOCLONAL ANTIBODIES, COMPOSITIONS, METHODS AND USES								
APPLICANT(S) FOR DO/EO/US: Mercken et al.								
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:								
1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.								
2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.								
This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below								
4.	☑ The US has been elected (Article 31).							
5. A copy of the International Application	☑ A copy of the International Application as filed (35 U.S.C. 371(c)(2))							
<ul> <li>a. \( \subseteq \) is attached hereto (required only if not communicated by the International Bureau).</li> <li>b. \( \subseteq \) has been communicated by the International Bureau.</li> <li>c. \( \subseteq \) is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ul>								
6.	An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).							
a. ☐ is attached hereto b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).								
7. Amendments to the claims of the Inter	☑ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))							
<ul> <li>b.  have been communicated by the</li> </ul>	the time limit for making such amenda							
8.	☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).							
9. X Two (2) Powers of Attorney or Authoriz	Two (2) Powers of Attorney or Authorization of Agent of the inventor(s) (35 U.S.C. 371(c)(4)).							
10. An English language translation of the Article 36 (35 U.S.C. 371(c)(5)).	An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).							
Items 11 to 20 below concern document	(s) or information included:							
11.	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.							
12. An assignment document for recording	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.							
13. 🛛 A preliminary amendment.	. 🔀 A preliminary amendment.							
14.	☐ An Application Data Sheet under 37 CFR 1.76.							
5. A substitute specification.								
16.  A power of attorney and/or change of a	☐ A power of attorney and/or change of address letter.							
17. A computer-readable form of the seque	☑ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.							
18.  A second copy of the published Interna	A second copy of the published International Application under 35 U.S.C. 154(d)(4).							
19. A second copy of the English language	A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).							
20.  Other items or information: Report and Claim for Priority.								

This collection of information is required by 37 CFR 1.414 AND 1.491-1.492. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Page 1 of 2

JC06 Rec'd PCT/PTO 23 MAR 2005

PTO-1390(Rev. 12-2004)

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION	<b>୬</b> 5028096	PCT/EP03/50276		ATTORNEY'S DOCKET NUMBER PRD-0032-USPCT1			
21.   The following fees are submitted:				Applicant use	Office use only		
x a) Basic national	fee		\$300	.00		\$ 300.00	
X b) Examination fee\$200.00					\$ 200.00		
X c) Search fee	•••••		\$50	0.00		\$ 500.00	
TOTAL OF ABOVE CALCULATIONS = \$ 1000.00						\$ 1,000.00	
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.							
Total Sheets	Extra sheets		Number of each additional 50 or fraction thereof (round up to a whole number				
- 100 =	/50 =				× \$250.00	\$ 0.00	
Surcharge of \$130 claimed priority dat	00 for furnishing the e (37 CFR 1.492(e))	oath or decl	laration later than 30 mon	ths from	the earliest	\$ 0.00	
CLAIMS	NUMBER FILE	D	NUMBER EXTRA	RAT	ΓE		
Total claims	15	-20	0	x \$	50.00		
Independent claims	2	- 3	0	x 2	00.00		
MULTIPLE DEPEN	IDENT CLAIM(S) (if	applicable)			300.00	\$0.00	
TOTAL OF ABOVE CALCULATIONS =					\$1,000.00		
Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by ½					\$0.00		
SUBTOTAL =					\$1,000.00		
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).					\$0.00		
TOTAL NATIONAL FEE =					\$1,000.00		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +					\$40.00		
TOTAL FEES ENCLOSED =					\$1,040.00		
Amount to be refunded:					e refunded:		\$
Amount to be charged:						\$1,040.00	
a. A check in the amount of \$ to cover the above fees is enclosed.							
<ul> <li>Dlease charge my Deposit Account No. 10-0750/PRD-0032-USPCT1/LAD in the amount of \$1,040.00 to cover the above fees.         A duplicate copy of this sheet is enclosed.     </li> </ul>							
c.  The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 10-0750/PRD-0032-USPCT1/LAD. A duplicate copy of this sheet is enclosed.							
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit Card information should not be included on this form. Provide credit card information and authorization on PTO-2038.							
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.							
One Johnson & Johnson Plaza			Nam	ne: Laura A. Do Reg. No. rney for Applica	38,435		

JC14 Rec'd PCT/PTO 23 MAR 2005

DOCKET NO.: PRD-0032-USPCT1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Mercker et al.

For:

N-11 TRUNCATED AMYLOID-BETA MONOCLONAL ANTIBODIES.

COMPOSITIONS, METHODS AND USES

Filed:

I.A. 09.09.2003

Serial No:

Unassigned

**VERIFIED STATEMENT UNDER 37 CFR §1.821(f)** 

I hereby verify that the computer readable diskette and paper copy enclosed herewith includes the same information as provided in the Sequence Listing of the subject application, and that this statement is made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully Submitted,

Laure i. Danelly Laura A. Donnelly

Registration No. 38,435

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-1729 (direct) (732) 524-2134 (facsimile)

Dated: March 23, 2005

## 10/528928

## JC06 Rec'd PCT/PTO 23 MAR 2009

·	
Serial No.	Docket No. <u>PLD</u> -0032-US 1CT By: LAD
Application of: Mercken et al	Mailed: March 23, 2005
Entitled: N-11 Municipled Am	y/oid-geta monoclaral
Antibodis, campositus, ma	thos and Us
THE FOLLOWING HAS BEEN RECEIVED IN T	HE U.S. PATENT OFFICE ON THE DATE STAMPED HEREON:
☐ Provisional ☐ Nonprovisional ☐ CP	A DRCE D CIP Divisional Design DPCT
Dath or Declaration (2) lxec	Express Mail Certificate
Assignment / wm/ucadata	n X# EL960327441 W
☐ Fee Transmittal Carly Welt	Specification 41 pgs (& Fled)
Charge to Deposit Account 10-0750	Claims 16
Priority Document NO 254/0296	
□ Data Sheet and Starch.	NUDUT Nereliminary Amendment 689
DS-Form 1449 Preliminary Ex	Sequence Listings/Diskette
☐ Extension of Time	1 n/0/T U Biological Deposit Declaration
PTO 1390 (PCT) prior ty 6 plays	1 Other Ventrata statement